• 1
    Kamm MA. The role of psychosocial factors in functional gut disease. Eur J Surg 1998; 164: 3740.
  • 2
    Kamm MA. Entry criteria for drug trials of irritable bowel syndrome. Am J Med 1999; 107(5A): 51S58S.
  • 3
    Drossman DA, Corrazziari E, Talley NJ, Thompson WG, Whitehead WE. The Functional Gastrointestinal Disorders, 2nd edn. McLean, VA, USA: Degnon Associates, 20002000.
  • 4
    Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 1530.
  • 5
    Goldberg PA, Kamm MA, Setti-Carraro P, Van Der Sijp JRM, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (Ondansetron). Digestion 1996; 57: 47883.
  • 6
    Smalley W, Shatin D, Wysowski DK, et al.Contraindicated use of cisapride: impact of food and drug administration regulatory action. J Am Med Assoc 2000; 284: 30369.
  • 7
    Federal Drug Administration (USA) Website. [2/12/2001].
  • 8
    Ferriman A. News. UK licence for cisapride suspended. Br Med J 2000; 321: 259259.
  • 9
    Miura M, Lawson DC, Clary EM, et al.Central modulation of rectal-distension induced blood pressure changes by alosteron, a 5-HT3 receptor antagonist. Dig Dis Sci 1999; 44: 204.
  • 10
    Zerbib F, Bruley des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosteron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 4037.
  • 11
    Delvaux M, Louvel D, Mamet J-P, et al.Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 84955.DOI: 10.1046/j.1365-2036.1998.00375.x
  • 12
    Camilleri M, Nortcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 103540.
  • 13
    Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984; 25: 16873.
  • 14
    Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1994; 29: 23947.
  • 15
    Gwee KA, Graham JC, McKendrick MW, et al.Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 1503.
  • 16
    Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 27789.
  • 17
    Lefkowitz M, Ligozio G, Heggland J, Dunger-Baldauf C, Ruegg PC. Tegaserod is well tolerated in patients with diarrhoea-predominant irritable bowel syndrome. Gut 2000; 47 (Suppl. 3): A217A217(Abstract).
  • 18
    Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42: 5116.
  • 19
    Emmanuel AV, Nicholls T, Roy AJ, Antonelli K, Kamm MA. Prucalopride imporves colonic transit and stool frequency in patients with slow and normal transit constipation. Gastroenterology 2000; 118: A846A846(Abstract).
  • 20
    Johanson JF, Miner PB, Parkman HP, Wojcik RL, Karcher K, Woods M. Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: results of two double-blind, placebo-controlled trials. Gastroenterology 2000; 118: A175A175(Abstract).
  • 21
    Fischler B, De Gucht V, Tack J, Janssens J. Psychosocial and psychopathological correlates of hypersensitivity to gastric distension in functional dyspepsia. Gastroenterology 1999; 116: A163A163(Abstract).
  • 22
    Fischler B, De Gucht V, Tack J, Janssens J. Relationship between job stress and physiopathological mechansims in functional dyspepsia. Gastreonterology 1999; 116: A163A163(Abstract).
  • 23
    Tack J, Piessevaux H, Coulie B, Janssens J. Influence of a fundus-relaxing drug on meal-related symptoms in dyspeptic patients with hyper-sensitivity to gastric distension. Gastroenterology 1999; 116: A324A324(Abstract).
  • 24
    Tack J, Piessevaux H, Coulie B, Fischler B, De Gucht V, Janssens J. A placebo-controlled trial of buspirone, a fundus-relaxing drug, in functional dyspepsia: effect on symptoms and gastric sensory and motor function. Gastroenterology 1999; 116: A325A325(Abstract).
  • 25
    Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8: 40916.
  • 26
    Creed FH, Fernandes L, Guthrie E, et al.The cost-effectiveness of psychotherapy and SSRI antidepressants for severe irritable bowel syndrome. Gastroenterology 2001; 120(Suppl. 1): A115A115(Abstract).
  • 27
    Camilleri M. Review article: clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 4853.
  • 28
    Herbst F, Kamm MA, Nicholls RJ. Effects of loperamide on ileoanal pouch function. Br J Surg 1998; 85: 142832.DOI: 10.1046/j.1365-2168.1998.00860.x
  • 29
    Harris AG, O'Dorisio TM, Woltering EA, et al.Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40(7): 146473.